New pill shows promise for Hard-to-Treat lymphoma patients
NCT ID NCT07459608
First seen May 01, 2026 · Last updated May 15, 2026 · Updated 4 times
Summary
This study tests a daily oral drug called lisaftoclax in 75 adults with slow-growing lymphomas (CLL, WM, or MZL) who cannot take or have stopped responding to standard treatments. The goal is to see if the drug is safe and can shrink or control the cancer. Treatment continues as long as it works and side effects are manageable.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for INDOLENT LYMPHOMA are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Henan cancer hospital
Zhengzhou, Henan, China
Conditions
Explore the condition pages connected to this study.